Dr. Mott Discusses Targeted Therapy for ALK+ NSCLC

Frank E. Mott, MD, FACP
Published: Friday, Nov 03, 2017



Frank E. Mott, MD, FACP, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses taregeted therapy for ALK-positive non-small cell lung cancer (NSCLC).

ALK-positive tumors represent 2% to 4% of NSCLC. There are new data demonstrating that patients respond much better to chemotherapy, states Mott.

According to Mott, newer agents, such as alectinib (Alcensa), are showing durable responses and progression-free survival for patients with central nervous system (CNS) metastases.
 


Frank E. Mott, MD, FACP, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses taregeted therapy for ALK-positive non-small cell lung cancer (NSCLC).

ALK-positive tumors represent 2% to 4% of NSCLC. There are new data demonstrating that patients respond much better to chemotherapy, states Mott.

According to Mott, newer agents, such as alectinib (Alcensa), are showing durable responses and progression-free survival for patients with central nervous system (CNS) metastases.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x